Exploring a new treatment approach for Alzheimer's Disease through autophagy modulation
Evaluating autophagy modulation as a therapeutic strategy for Alzheimer's Disease using human neuronal culture models
This study is looking at a new way to help people with Alzheimer's by testing a special compound that might help brain cells clear out harmful proteins, which could improve memory and thinking skills.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-10922723 on NIH RePORTER |
What this research studies
This research investigates how enhancing the autophagic lysosomal pathway (ALP) could serve as a potential treatment for Alzheimer's Disease. By using human neuronal culture models, the study aims to understand how this pathway can help clear misfolded proteins that contribute to cognitive decline. The researchers will test a novel compound that has shown promise in preliminary studies for its ability to activate autophagy and improve protein degradation in neurons. This approach seeks to address the limitations of current Alzheimer's treatments by targeting multiple pathways involved in the disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's Disease or those at risk of developing it.
Not a fit: Patients with other forms of dementia unrelated to Alzheimer's may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new therapeutic strategy that significantly slows cognitive decline in Alzheimer's patients.
How similar studies have performed: While the approach of modulating autophagy in Alzheimer's is still being explored, preliminary data suggests potential success, indicating a novel avenue for treatment.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Snead, Amanda — University of Illinois at Chicago
- Study coordinator: Snead, Amanda
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.